Tissue | Dose of 5F11-scFv-SA (μg) | ||||||
---|---|---|---|---|---|---|---|
100 | 300 | 900 | 2,400 | ||||
Adrenal | 19.7 ± 5.5 | 65.3 ± 20.3 | 124.6 ± 20.9 | 193.1 ± 7.1 | |||
Bladder | 22.8 ± 4.3 | 29.1 ± 3.8 | 145.2 ± 44.4 | 92.1 ± 7.6 | |||
Blood | 139.4 ± 30.3 | 160.9 ± 17.3 | 1,121.3 ± 306 | 621.4 ± 61.5 | |||
Brain | 170.9 ± 12.6 | 503 ± 100.6 | 1187 ± 268 | 901.6 ± 157.4 | |||
Femur | 67.3 ± 11 | 169.4 ± 27.1 | 405.2 ± 38.1 | 288.8 ± 41.9 | |||
Heart | 34.3 ± 4 | 110.8 ± 13.3 | 265 ± 30.9 | 269.7 ± 11 | |||
Kidney | 1.1 ± 0.3 | 2.7 ± 0.6 | 10.6 ± 2.9 | 7.1 ± 0.2 | |||
Large intestine | 3.7 ± 1 | 17.4 ± 3.9 | 15.9 ± 3.2 | 10.2 ± 1.7 | |||
Liver | 10 ± 1.6 | 18.5 ± 2.6 | 50.3 ± 11.9 | 37 ± 1.5 | |||
Lung | 19.8 ± 3.1 | 21.8 ± 3.4 | 62.8 ± 21.5 | 23.1 ± 2.3 | |||
Muscle | 35.8 ± 6.1 | 160.7 ± 22.9 | 467 ± 61.4 | 429 ± 39 | |||
Skin | 13.3 ± 1.9 | 23.6 ± 4.4 | 51.4 ± 3.9 | 56.6 ± 8.3 | |||
Small intestine | 37.4 ± 7 | 66 ± 9.2 | 135.6 ± 33.1 | 114.3 ± 24.9 | |||
Spine | 49.2 ± 5.9 | 130.8 ± 20 | 425.4 ± 58.8 | 338.6 ± 27.2 | |||
Spleen | 14.8 ± 2.2 | 30.8 ± 4.1 | 118.2 ± 12.3 | 120.2 ± 5.8 | |||
Stomach | 48.2 ± 14.9 | 94.7 ± 12.4 | 181.7 ± 30.7 | 70.6 ± 5.2 | |||
Tumor %ID/g | 1.9 ± 0.5 | 3.1 ± 0.9 | 6.5 ± 1.5 | 7.4 ± 0.5 |
T/NT ratio was calculated as follows: (%ID/g in tumor)/(%ID/g in tissue). Athymic nude mice xenografted with established human NB LAN-1 (0.5- to 0.8-cm diameter) were injected intravenously with 5F11-SA, followed in 24 h by intravenous injection of sCA biotin-LC-NM-(Gal-NAc)16, and then 4 h later injected intravenously with ∼2.5 μg 111In-DOTA-biotin. Mice were killed 24 h after 111In-DOTA-biotin for biodistribution studies. Four dose levels of 5F11-SA were tested: 100, 300, 900, and 2,400 μg (n = 5 mice per group). Dose of sCA was 50% (weight ratio) of 5F11-scFv-SA dose. T/NT ratio was summarized for each organ as arithmetic mean ± SEM.